Skip to content

Beyond addiction: a randomized controlled trial on the effectiveness of group schema therapy in patients with dual diagnosis

Beyond addiction: a randomized controlled trial on the effectiveness of group schema therapy in patients with dual diagnosis - Beyond addiction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55529
Enrollment
106
Registered
2018-05-24
Start date
2019-03-27
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dual Diagnosis Substance disorder with comorbid psychiatric disorder(s)

Interventions

Patients assigned to the experimental condition will receive 30 weekly sessions (2 hours) of G-ST, plus 3 preparatory individual meetings. Patients in the control condition will also start with 3 in

Sponsors

Parnassia Bavo Groep (Den Haag)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - the presence of a Dual Diagnosis (i.e. having a Substance Use Disorder, except only nicotine use disorder, and one or more DSM-5 diagnoses other than a substance use disorder, including at least one Personality Disorder) - between 18 and 65 years of age - willing to participate in the study.

Exclusion criteria

Exclusion criteria: - an IQ below 80 (in case of doubt an intelligence test is administered) - problems with speaking, reading and/or writing the Dutch language - having mental health problems that require other treatment (i.e. the presence of schizophrenia, bipolar disorder type 1, acute suicidality and/or SUD that needs immediate detoxification) - personality traits (e.g. aggression outbursts, being indifferent to mistreating others) that make it difficult to participate in a group context and - having received ST and/or CGT for addiction problems for more than three months duration in the past year.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure will be the difference between the two treatment groups on general psychopathology as measured by the Symptom Check List (SCL-90).

Secondary

MeasureTime frame
The secondary outcome measure will be the difference in addiction severity between the two groups. This will be investigated by a subtest of the Addiction Severity Index (ASI). An important process measure will be emotion regulation and will be measured by the Emotion Regulation Questionnaire (EQ).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)